BRIEF-Syncona Portfolio Ltd Submitted Non-Binding Proposal To Freeline Therapeutics Holdings

Reuters2023-10-18

Oct 18 (Reuters) - Freeline Therapeutics Holdings PLC

* SYNCONA PORTFOLIO LTD SAYS ON OCT 17, SUBMITTED NON-BINDING PROPOSAL TO FREELINE THERAPEUTICS HOLDINGS - SEC FILING

* SYNCONA PORTFOLIO LTD SAYS TO ACQUIRE ALL OF OUTSTANDING ORDINARY SHARES OF FREELINE THERAPEUTICS, NOT CURRENTLY OWNED BY SYNCONA AND AFFILIATES

* SYNCONA PORTFOLIO - INTENDS TO ENGAGE IN DISCUSSIONS WITH FREELINE THERAPEUTICS AND REPRESENTATIVES CONCERNING NON-BINDING PROPOSAL

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2376153274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-18 18:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2376153274","market":"us","top_or_hot":-1,"title":"BRIEF-Syncona Portfolio Ltd Submitted Non-Binding Proposal To Freeline Therapeutics Holdings","media":"Reuters","content":"<html><body><p>Oct 18 (Reuters) - Freeline Therapeutics Holdings <a href=\"https://laohu8.com/S/PLC\">PLC</a></p><p> :</p><p>   * <a href=\"https://laohu8.com/S/SYNC.UK\">SYNCONA</a> PORTFOLIO LTD SAYS ON OCT 17, SUBMITTED NON-BINDING PROPOSAL TO FREELINE THERAPEUTICS HOLDINGS - SEC FILING</p><p>   * SYNCONA PORTFOLIO LTD SAYS TO ACQUIRE ALL OF OUTSTANDING ORDINARY SHARES OF FREELINE THERAPEUTICS, NOT CURRENTLY OWNED BY SYNCONA AND AFFILIATES</p><p>   * SYNCONA PORTFOLIO - INTENDS TO ENGAGE IN DISCUSSIONS WITH FREELINE THERAPEUTICS AND REPRESENTATIVES CONCERNING NON-BINDING PROPOSAL</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Syncona Portfolio Ltd Submitted Non-Binding Proposal To Freeline Therapeutics Holdings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Syncona Portfolio Ltd Submitted Non-Binding Proposal To Freeline Therapeutics Holdings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-18 18:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 18 (Reuters) - Freeline Therapeutics Holdings PLC :   * SYNCONA PORTFOLIO LTD SAYS ON OCT 17, SUBMITTED NON-BINDING PROPOSAL TO FREELINE THERAPEUTICS HOLDINGS - SEC FILING   * SYNCONA PORTFOLIO ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2376153274","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2376153274","pubTimestamp":1697625712,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 18  - Freeline Therapeutics Holdings PLC :   * SYNCONA PORTFOLIO LTD SAYS ON OCT 17, SUBMITTED NON-BINDING PROPOSAL TO FREELINE THERAPEUTICS HOLDINGS - SEC FILING   * SYNCONA PORTFOLIO LTD SAYS TO ACQUIRE ALL OF OUTSTANDING ORDINARY SHARES OF FREELINE THERAPEUTICS, NOT CURRENTLY OWNED BY SYNCONA AND AFFILIATES   * SYNCONA PORTFOLIO - INTENDS TO ENGAGE IN DISCUSSIONS WITH FREELINE THERAPEUTICS AND REPRESENTATIVES CONCERNING NON-BINDING PROPOSALSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FRLN":"Freeline Therapeutics Holdings plc"},"translate_title":"简介-Syncona Portfolio Ltd向Freeline Therapeutics Holdings提交非约束性建议书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FRLN":0.9},"content_text":"Oct 18 (Reuters) - Freeline Therapeutics Holdings PLC :   * SYNCONA PORTFOLIO LTD SAYS ON OCT 17, SUBMITTED NON-BINDING PROPOSAL TO FREELINE THERAPEUTICS HOLDINGS - SEC FILING   * SYNCONA PORTFOLIO LTD SAYS TO ACQUIRE ALL OF OUTSTANDING ORDINARY SHARES OF FREELINE THERAPEUTICS, NOT CURRENTLY OWNED BY SYNCONA AND AFFILIATES   * SYNCONA PORTFOLIO - INTENDS TO ENGAGE IN DISCUSSIONS WITH FREELINE THERAPEUTICS AND REPRESENTATIVES CONCERNING NON-BINDING PROPOSALSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2376153274"}